Terms: = Pancreatic cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Diagnosis
24 results:
1. [Practical application of immunohistochemistry in pancreatic neuroendocrine neoplasms : Tips and pitfalls].
Bräutigam K; Chouchane A; Konukiewitz B; Perren A
Pathologie (Heidelb); 2024 Feb; 45(1):35-41. PubMed ID: 38175232
[TBL] [Abstract] [Full Text] [Related]
2. NET G3 vs NEC: p53 and rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract] [Full Text] [Related]
3. Integrated Genomic and Clinicopathologic Approach Distinguishes pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract] [Full Text] [Related]
4. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms.
Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP
J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558
[TBL] [Abstract] [Full Text] [Related]
6. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
[TBL] [Abstract] [Full Text] [Related]
7. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.
Kasajima A; Konukiewitz B; Schlitter AM; Weichert W; Klöppel G
Virchows Arch; 2022 Feb; 480(2):359-368. PubMed ID: 34499237
[TBL] [Abstract] [Full Text] [Related]
8. Kinesin 12 (KIF15) contributes to the development and tumorigenicity of prostate cancer.
Qureshi Z; Ahmad M; Yang WX; Tan FQ
Biochem Biophys Res Commun; 2021 Oct; 576():7-14. PubMed ID: 34474246
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract] [Full Text] [Related]
10. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
[TBL] [Abstract] [Full Text] [Related]
11. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
[TBL] [Abstract] [Full Text] [Related]
12. Metastatic Plasmacytoid Bladder cancer Harboring a CDH-1 Mutation and Producing High Levels of CA 19-9. A Case Report and Literature Review.
Telfah M; Parikh RA; Zhang D; Kasi A
Am J Case Rep; 2020 Jul; 21():e923130. PubMed ID: 32644978
[TBL] [Abstract] [Full Text] [Related]
13. [A Case of Resected Metachronous pancreatic Metastasis from Rectal Carcinoma].
Sakai K; Ohashi T; Shimura Y; Teranishi R; Hara S; Takayama K; Yoshida M; Yoneda K; Osawa H; Ide Y; Noro H; Hirao T; Iwasaki T; Hatanaka N; Yamasaki Y
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2306-2308. PubMed ID: 32156913
[TBL] [Abstract] [Full Text] [Related]
14. Role of ferroptosis in hepatocellular carcinoma.
Nie J; Lin B; Zhou M; Wu L; Zheng T
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2329-2337. PubMed ID: 30167889
[TBL] [Abstract] [Full Text] [Related]
15. Integrated analysis of gene expression and copy number variations in MET proto‑oncogene‑transformed human primary osteoblasts.
Jia RJ; Lan CG; Wang XC; Gao CT
Mol Med Rep; 2018 Feb; 17(2):2543-2548. PubMed ID: 29207108
[TBL] [Abstract] [Full Text] [Related]
16. Somatostatin receptor expression related to TP53 and rb1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
[TBL] [Abstract] [Full Text] [Related]
17. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
Lewis CS; Voelkel-Johnson C; Smith CD
Oncotarget; 2016 Sep; 7(37):60181-60192. PubMed ID: 27517489
[TBL] [Abstract] [Full Text] [Related]
18. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract] [Full Text] [Related]
19. Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy.
Pelizzaro-Rocha KJ; de Jesus MB; Ruela-de-Sousa RR; Nakamura CV; Reis FS; de Fátima A; Ferreira-Halder CV
Biochim Biophys Acta; 2013 Dec; 1833(12):2856-2865. PubMed ID: 23872419
[TBL] [Abstract] [Full Text] [Related]
20. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
[TBL] [Abstract] [Full Text] [Related]
[Next]
